The American Association of Clinical Endocrinologists and The American Association of Endocrine Surgeons Position Statement on The Diagnosis and Management of Primary Hyperparathyroidism

Kukora, John S.; Zeiger, Martha A.; Clark, Orlo H.; Grant, Clive S.; Hodgson, Stephen F.; Irvin, George L.; Kleerekoper, Michael; Pasieka, Janice L.; Shaha, Ashok R.; Thompson, Geoffrey B.; Heerden, Jon A. van; Weber, Collin J.

doi:10.4158/ep.11.1.49

Cited by 205 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Соотношение мужчин и жен-щин -1:3. Ежегодная заболеваемость варьирует от 0,4-18,8 случаев на 10 000 человек в зависимости от качества диспансерного обслуживания [6][7][8][9][10][11][12].…”

Section: клинические рекомендацииunclassified

“…Бо-лее того, снижение СКФ менее 60 мл/мин/1,73 кв.м является показанием к хирургическому лечению мягких форм ПГПТ [2,9]. Поэтому исследование креатинина крови и расчет СКФ можно отнести к обязательным исследованиям при ПГПТ.…”

Section: 6unclassified

“…При этом оцени-вают состояние отделов скелета с преимущественно кортикальным строением кости, поэтому помимо стандартного исследования состояния осевого ске-лета (поясничного отдела позвоночника и прокси-мального отдела бедренной кости) необходимо оце-нивать состояние периферических костей (предпле-чья), имеющих преимущественно кортикальное строение и подвергающихся наибольшему воздей-ствию ПТГ [2,3,9,48].…”

Section: сцинтиграфию с 99munclassified

“…Костные потери в периферическом скелете сначала выявляются в концевых отделах трубчатых костей вследствие преобладания здесь губ-чатой кости. Эндостальная резорбция играет главную роль при ПГПТ [3,9,[50][51][52].…”

Section: сцинтиграфию с 99munclassified

“…Почечная недо-статочность является одним из наиболее тяжелых и малообратимых осложнений и связана с более вы-раженными клиническими проявлениями, повы-шением риска смерти, увеличением распространен-ности артериальной гипертензии [2,9,55]. Cниже-ние СКФ до ХБП 3-й стадии диагностируется у 17-20% с ПГПТ, при этом часть пациентов могут иметь мягкую форму заболевания [56].…”

Section: сцинтиграфию с 99munclassified

See 4 more Smart Citations

Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment

Dedov

Иванович²,

Мельниченко

et al. 2017

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Primary hyperparathyroidism (PHT) is the third most common endocrine disorder in men and women after diabetes mellitus and thyroid disease and one of the most frequent causes of osteoporosis and fractures among the secondary osteopathy. PHT refers to socially significant problems in connection with involvement in the pathological process of the majority of organs and system In recent years, the conception of epidemiology, clinic and tactics of management of patients with PHT has changed due to significant increase of morbidity at the expense of identification of mild forms of disease. The modern management concept tactics depends on clinical manifestations. Bearing in mind the importance of the problem under consideration, the working group was set up for the development of federal recommendations on the treatment of PHT based on the principles of evidence-based medicine. The experience accumulated by the domestic and international experts was summarized in the federal clinical guidelines on PHT.

show abstract

Section: клинические рекомендацииunclassified

Section: 6unclassified

Section: сцинтиграфию с 99munclassified

See 3 more Smart Citations

Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment

Dedov

Иванович²,

Мельниченко

et al. 2017

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

show abstract

The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism

VanderWalde

Liu²,

O’Connell³

et al. 2006

Arch Surg

View full text Add to dashboard Cite

show abstract

Sunitinib‐induced hyperparathyroidism

Bassareo

Tassi

Lapini³

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Sunitinib malate is an orally bioavailable tyrosine kinase inhibitor that is active against many tyrosine kinase receptors involving crucial pathways in both healthy tissues and malignant tissues. Because its use in clinical practice is quite recent, many of its possible side effects remain unknown. In this report, the authors describe the incidence of new-onset hyperparathyroidism in a cohort of patients with metastatic renal cell carcinoma who received treatment with sunitinib. METHODS: Twenty-six patients who received first-line sunitinib for metastatic renal cell carcinoma were enrolled in this study for a mineral and parathyroid function assessment. Plasma levels of intact parathyroid hormone; serum levels of calcium, phosphorus, 25-hydroxyvitamin D 3 , and 1,25-dihydrovitamin D 3 ; and urinary 24-hour calcium and phosphorus excretion all were measured in each patient. Biochemical evaluations were performed before the beginning of treatment and at the end of each sunitinib treatment period. RESULTS: Eighteen of 26 patients (69.2%) developed hyperparathyroidism with normal serum calcium levels, and 6 of them developed hypophosphatemia. Patients presented with a mean elevation of parathyroid hormone after 2.2 cycles of sunitinib. The levels of 25-OH vitamin D 3 were stable over the course of treatment, whereas 1,25-OH vitamin D 3 levels were increased in 5 hyperparathyroid patients. Those who presenting with elevated parathyroid hormone levels had low or undetectable urinary calcium levels. Parathyroid hormone elevation usually persisted but did not progress during long-term therapy with sunitinib. Permanent treatment interruption resulted in a resolution of hyperparathyroidism. CONCLUSIONS: Hyperparathyroidism developed in an high percentage of patients on sunitinib. Therefore, the authors concluded that sunitinib may affect parathyroid function and bone mineral homeostasis, possibly resulting in abnormal bone remodeling. Cancer 2012;118:3165-

show abstract

The American Association of Clinical Endocrinologists and The American Association of Endocrine Surgeons Position Statement on The Diagnosis and Management of Primary Hyperparathyroidism

Cited by 205 publications

References 26 publications

Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment

Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment

The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism

Sunitinib‐induced hyperparathyroidism

Contact Info

Product

Resources

About